ArticleInternational journal of imaging systems and technology2023
Non-invasive prediction of overall survival time for glioblastoma multiforme patients based on multimodal MRI radiomics.
Article in International journal of imaging systems and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Survival prediction of glioblastoma patients using machine learning and deep learning: a systematic review.BMC cancer · 2024Pooled it
- Machine learning-based integration of dosiomics and pre-radiotherapy multimodal MRI radiomics for survival stratification in patients with glioblastoma multiforme.Radiation oncology (London, England) · 2025Article
- AI-Driven Innovations in Neuroradiology and Neurosurgery: Scoping Review of Current Evidence and Future Directions.Cancers · 2025Review
- A Radiomic Model for Gliomas Grade and Patient Survival Prediction.Bioengineering (Basel, Switzerland) · 2025Article
- Non-invasive prediction of overall survival time for glioblastoma multiforme patients based on multimodal MRI radiomics.International journal of imaging systems and technology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Glioblastoma multiforme (GBM) is the most common and deadly primary malignant brain tumor. As GBM tumor is aggressive and shows high biological heterogeneity, the overall survival (OS) time is extremely low even with the most aggressive treatment. If the OS time can be predicted before surgery, developing personalized treatment plans for GBM patients will be beneficial. Magnetic resonance imaging (MRI) is a commonly used diagnostic tool for brain tumors with high-resolution and sound imaging effects. However, in clinical practice, doctors mainly rely on manually segmenting the tumor regions in MRI and predicting the OS time of GBM patients, which is time-consuming, subjective and repetitive, limiting the effectiveness of clinical diagnosis and treatment. Therefore, it is crucial to segment the brain tumor regions in MRI, and an accurate pre-operative prediction of OS time for personalized treatment is highly desired. In this study, we present a multimodal MRI radiomics-based automatic framework for non-invasive prediction of the OS time for GBM patients. A modified 3D-UNet model is built to segment tumor subregions in MRI of GBM patients; then, the radiomic features in the tumor subregions are extracted and combined with the clinical features input into the Support Vector Regression (SVR) model to predict the OS time. In the experiments, the BraTS2020, BraTS2019 and BraTS2018 datasets are used to evaluate our framework. Our model achieves competitive OS time prediction accuracy compared to most typical approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.